GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Analysis of Expression of Specific Markers and Their Prognostic Significance in Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Other: Retrospective analysis of already archived samples
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 200
- Registration Number
- NCT00911196
- Locations
- 🇹🇭
GSK Investigational Site, Chiangmai, Thailand
Evaluation of Fondaparinux in Patients With a Heart Rhythm Disturbance Who Undergo Restoration of Normal Heart Rhythm
- Conditions
- Fibrillation, Atrial
- Interventions
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2012-10-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 349
- Registration Number
- NCT00911300
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 526
- Registration Number
- NCT00910962
- Locations
- 🇬🇧
GSK Investigational Site, Paddington, London, United Kingdom
Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With the Same Vaccine
- Conditions
- Infections, Streptococcal
- Interventions
- Biological: GSK Biologicals' Synflorix™ (Pneumococcal vaccine GSK1024850A)Biological: Wyeth-Lederle's Prevenar™Biological: GSK Biologicals' Hiberix™
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2018-09-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 450
- Registration Number
- NCT00911144
- Locations
- 🇰🇷
GSK Investigational Site, Wonju-si Kangwon-do, Korea, Republic of
Effects of GSK598809 on Brain Activation in Abstinent Alcoholics
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00908206
Intranasal SB-705498 in Healthy Volunteers
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 44
- Registration Number
- NCT00907933
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
A Study to Evaluate the Effect of Single Doses of Drug A (Lamotrigine) and Drug B (Vofopitant) Alone and in Combination on Resting Motor Threshold in Healthy Subjects
- Conditions
- Bipolar Disorder
- Interventions
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT00907985
- Locations
- 🇩🇪
GSK Investigational Site, Goettingen, Niedersachsen, Germany
Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™
- Conditions
- Infections, StreptococcalStreptococcus Pneumoniae
- Interventions
- Biological: Pneumococcal conjugate vaccine Prevenar™ (Wyeth Lederle's)Biological: Pneumococcal conjugate vaccine GSK 1024850A
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 52
- Registration Number
- NCT00907777
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)
- Conditions
- Purpura, Thrombocytopaenic, Idiopathic
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 82
- Registration Number
- NCT00908037
- Locations
- 🇬🇧
GSK Investigational Site, Southampton, United Kingdom
Post Market Surveillance for Infanrix™
- Conditions
- TetanusAcellular PertussisDiphtheria
- Interventions
- Biological: GSK Biologicals' Infanrix™
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1258
- Registration Number
- NCT00908115
- Locations
- 🇰🇷
GSK Investigational Site, Daegu, Korea, Republic of